Indeed, cetuximab was shown to inhibit the pathways involved in cell proliferation, cell survival and tumor invasion (i.e., the RAS–RAF–mitogen-activated protein kinase 1 (MAPK1) and the v-AKT murine thymoma viral oncogene homolog 1 (AKT1) axis) in cells overexpressing EGFR but not in KRAS-mutated tumors. This evidence concerns the gene AKT1 and neoplasm.